ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1509

Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 2389

Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Abstract Number: 2215

Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Abstract Number: 1164

Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Abstract Number: 0135

Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus
Abstract Number: 0143

Cancer Incidence in Familial Mediterranean Fever
Abstract Number: 1055

Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Abstract Number: 0607

CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Abstract Number: 1171

Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 0448

Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study
Abstract Number: 1343

Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years
Abstract Number: 1462

Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Abstract Number: 0467

Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Abstract Number: 1207

Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].